Trueline Therapeutics Inc.


Trueline's scientists recognized that if the HCK protein could be switched “off”, leukemic stem cells would lose a key survival mechanism, and chemo-resistant cancers would now become vulnerable. TTX-114 is the outcome of a structure-based optimization effort and will be clinically evaluated in hematological malignancies and certain lymphomas.

HCK/BTK Inhibitor

Uncovering cancer's hiding places

Following chemotherapy, leukemic cells can hide in the protective environment of bone marrow - rendering even the most powerful agents ineffective. An enzyme called HCK (hematopoietic cell kinase) has recently been shown to direct cancerous cells into hiding

Hello world

TTX-114 - HCK/BTK Inhibitor

Targeting the Achilles' Heel of cancer

Gene transcriptional analysis of patient-derived leukemic stem cells identified HCK as a master switch that turns “on” during the refractory or relapse stages of acute myeloid leukemia. Importantly, HCK plays a minor role in healthy, developing blood cells which enhances the likelihood of clinical safety with an HCK/BTK inhibitor.

BTK is a key partner of HCK in ensuring lymphoma cell survival. TTX-114 is designed to target both, HCK and BTK, tackling the Achilles' heel of cancer survival to overcome resistance to current standard of care.

For partnerships, investment opportunities, or to learn more about our work, contact us.